6.3 Hormonal Contraceptives, Naloxone & Public Health Protocols

6.3 Hormonal Contraceptives, Naloxone & Public Health Protocols

Quick Answer: Tennessee pharmacists possess expanded protocol-based prescribing and dispensing authority for critical public health therapeutics. Under T.C.A. § 63-10-219 and Tenn. Comp. R. & Regs. Chapter 1140-15, pharmacists who complete a Board-approved training program may prescribe self-administered hormonal contraceptives (oral pills, transdermal patch, vaginal ring, depot injection) to women who are at least 18 years old or emancipated minors. The pharmacist must administer a standardized CDC-based self-screening risk assessment, measure blood pressure in the pharmacy, exclude contraindications (e.g., BP ≥140/90 mmHg, migraine with aura, smoker ≥35), counsel the patient, provide a written summary, and refer them to a primary care physician. Under T.C.A. § 63-1-152, pharmacists may dispense naloxone under the Chief Medical Officer's statewide standing order to anyone at risk or third-party bystanders with mandatory counseling, backed by complete civil and criminal statutory immunity.

---

1. Hormonal Contraceptive Prescribing: Statutory Foundation & Collaborative Agreement

In 2016, the Tennessee General Assembly enacted legislation authorizing pharmacists to provide hormonal contraceptives directly to patients without an individualized prescriber visit (T.C.A. § 63-10-219). The Tennessee Board of Pharmacy, in consultation with the Tennessee Board of Medical Examiners, promulgated administrative regulations codified at Tenn. Comp. R. & Regs. Chapter 1140-15 (Hormonal Contraceptive Collaborative Pharmacy Practice).

The Administrative Mechanism

Pharmacist prescriptive authority for hormonal contraceptives operates under a statewide collaborative pharmacy practice agreement entered into between participating pharmacists and the Chief Medical Officer (CMO) of the Tennessee Department of Health (or alternatively, under a private CPPA with a licensed Tennessee physician).

┌─────────────────────────────────────────────────────────────────────────────┐
│            TENNESSEE HORMONAL CONTRACEPTIVE PRESCRIBING ARCHITECTURE         │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Statutory Authority: T.C.A. § 63-10-219                                  │
│ 2. Administrative Rules: Tenn. Comp. R. & Regs. Chapter 1140-15             │
│ 3. Master Agreement: Signed with TDH Chief Medical Officer or Private MD/DO │
│ 4. Pharmacist Prerequisite: Board-Approved Training Program Completed       │
│ 5. Clinical Protocol: CDC US Medical Eligibility Criteria (US MEC) Derived  │
│ 6. Practice Site Prerequisite: Dedicated Confidential Consultation Space   │
└─────────────────────────────────────────────────────────────────────────────┘

Mandatory Pharmacist Training Program

Before initiating contraceptive prescribing, the pharmacist must complete an accredited training program approved by the Tennessee Board of Pharmacy. The training curriculum must encompass:

• Pharmacology, mechanisms of action, pharmacokinetics, and efficacy rates of hormonal contraceptives.
• Application of the Centers for Disease Control and Prevention (CDC) United States Medical Eligibility Criteria for Contraceptive Use (US MEC).
• Clinical risk evaluation, identifying Category 3 and Category 4 contraindications.
• Patient consultation protocols, blood pressure measurement technique, and proper referral pathways for gynecologic care.

---

2. Eligible Contraceptive Formulations & Patient Eligibility Criteria

Authorized Formulations

Under T.C.A. § 63-10-219(a)(3) and Rule 1140-15-.01, "self-administered hormonal contraceptives" authorized for pharmacist prescribing include:

1. Oral Contraceptive Pills (OCPs): Both Combined Oral Contraceptives (COCs: estrogen + progestin) and Progestin-Only Pills (POPs: "minipills").
2. Transdermal Contraceptive Patch: Norelgestromin/ethinyl estradiol or levonorgestrel/ethinyl estradiol patches.
3. Vaginal Contraceptive Ring: Etonogestrel/ethinyl estradiol or segesterone/ethinyl estradiol rings.
4. Depot Medroxyprogesterone Acetate (DMPA): Subcutaneous or intramuscular depot injection (self-administered or clinic/pharmacist-administered).

[!CAUTION] Non-Covered Devices: Pharmacist prescribing authority under Chapter 1140-15 strictly excludes surgically implanted long-acting reversible contraceptives (LARCs), such as intrauterine devices (IUDs) and subdermal contraceptive implants (e.g., Nexplanon). These devices require clinical insertion by a licensed physician, APRN, or PA.

Patient Eligibility Rules

• Age Threshold: The patient must be at least eighteen (18) years of age, OR must be an emancipated minor under Tennessee law (e.g., declared emancipated by court decree or through legal marriage).
• Minor Ineligibility: A non-emancipated minor under age 18 cannot receive pharmacist-prescribed hormonal contraceptives under this protocol, even with parental consent. Non-emancipated minors must be evaluated directly by a traditional prescriber.

---

3. Mandatory Clinical Assessment & Contraindication Screening

Under Tenn. Comp. R. & Regs. 1140-15-.03, the pharmacist must execute a multi-step clinical assessment before issuing a prescription order:

┌─────────────────────────────────────────────────────────────────────────────┐
│                     CONTRACEPTIVE CLINICAL ASSESSMENT FLOW                  │
├─────────────────────────────────────────────────────────────────────────────┤
│ Step 1: Patient Self-Screening Questionnaire                                │
│         Patient completes standardized TDH/Board-approved questionnaire     │
│         evaluating medical history, medications, smoking, and symptoms.     │
│                                                                             │
│ Step 2: Mandatory In-Pharmacy Blood Pressure Measurement                    │
│         Pharmacist (or trained staff) measures sitting blood pressure       │
│         using a calibrated, validated sphygmomanometer.                     │
│                                                                             │
│ Step 3: Contraindication Screening (CDC US MEC Evaluation)                  │
│         Pharmacist reviews questionnaire + BP to detect contraindications.  │
│                                                                             │
│ Step 4: Product Selection & Prescribing                                     │
│         If eligible, prescribe selected formulation for up to 12 months.    │
│                                                                             │
│ Step 5: Counseling, Written Summary & Referral                              │
│         Provide counseling, deliver written visit summary, refer to PCP.    │
└─────────────────────────────────────────────────────────────────────────────┘

Absolute Contraindications (CDC US MEC Category 4)

Under the protocol, the pharmacist must NOT prescribe combined hormonal contraceptives (containing estrogen) to patients exhibiting any of the following contraindications:

• Uncontrolled or Elevated Blood Pressure: Systolic blood pressure ≥140 mmHg OR diastolic blood pressure ≥90 mmHg measured during the clinical encounter.
• Migraine with Aura: Migraine headaches accompanied by focal neurological aura (scintillating scotoma, visual field loss, numbness/tingling, speech difficulty) at any age (significantly heightened stroke risk).
• Thromboembolic History: Current or past history of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, ischemic heart disease, or known thrombogenic mutations (e.g., Factor V Leiden).
• Tobacco Smoking in Women Aged 35 or Older: Any current cigarette smoking in a patient aged 35 years or older.
• Breast Cancer: Current or past history of breast cancer or other estrogen-dependent neoplasia.
• Hepatic Impairment: Acute hepatitis, severe cirrhosis, or hepatic adenoma/carcinoma.
• Prolonged Immobilization: Major surgery with prolonged immobilization.

[!TIP] Alternative for Hypertensive or Older Smoking Patients: If a patient has an absolute contraindication to estrogen (such as controlled stage 1 hypertension or age ≥35 and smoking), the pharmacist may evaluate eligibility for Progestin-Only Pills (POPs) or DMPA, which do not carry the thromboembolic risks associated with systemic estrogen.

Required Patient Counseling & Documentation

Upon prescribing, the pharmacist must:

1. Counsel the patient regarding administration timing, missed-dose protocols, adverse effects (breakthrough bleeding, nausea), and explicitly emphasize that hormonal contraceptives do not protect against sexually transmitted infections (STIs/HIV) (condom usage must be recommended).
2. Provide the patient with a written consultation summary detailing the medication prescribed, dosing instructions, and vital signs recorded.
3. Strongly advise the patient to consult a primary care provider or obstetrician/gynecologist for regular preventive health screenings (Pap smears, pelvic exams, breast exams).
4. Retain all completed screening questionnaires, blood pressure logs, and dispensing records for ten (10) years.

---

4. Naloxone Dispensing Under Statewide Standing Order (T.C.A. § 63-1-152)

In response to the public health epidemic of opioid-related morbidity and mortality, Tennessee enacted T.C.A. § 63-1-152, establishing a comprehensive framework for community access to opioid antagonists.

The Statewide Standing Order

Under T.C.A. § 63-1-152(b), the Chief Medical Officer (CMO) of the Tennessee Department of Health is statutorily authorized to issue a statewide standing order for the dispensing of opioid antagonists.

• Any pharmacist licensed by the Tennessee Board of Pharmacy may dispense an approved opioid antagonist (such as naloxone hydrochloride) pursuant to this statewide standing order.
• The standing order functions as a legally valid prescription issued by the Chief Medical Officer, eliminating the need for an individual, patient-specific prescriber visit.

┌─────────────────────────────────────────────────────────────────────────────┐
│                     STATEWIDE NALOXONE STANDING ORDER MATRIX                │
├──────────────────────────┬──────────────────────────────────────────────────┤
│ Legal Authority          │ T.C.A. § 63-1-152 & TDH CMO Standing Order       │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Authorized Formulations  │ Naloxone 4 mg Intranasal Spray (e.g., Narcan),   │
│                          │ Naloxone Autoinjector, Naloxone 2 mg/2 mL for IM │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Eligible Recipients      │ 1. Person at risk of experiencing an opioid OD   │
│                          │ 2. Family member, friend, caregiver of at-risk   │
│                          │ 3. First responder or bystander able to assist   │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Third-Party Prescribing  │ Explicitly permitted: Recipient does NOT need to │
│                          │ be the ultimate end-user of the medication.      │
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Mandatory Education      │ Overdose recognition, 911 call, recovery position│
├──────────────────────────┼──────────────────────────────────────────────────┤
│ Liability Protections    │ Complete civil and criminal statutory immunity   │
└──────────────────────────┴──────────────────────────────────────────────────┘

Third-Party Dispensing Authority

A fundamental legal concept tested on the MPJE is third-party dispensing. Under T.C.A. § 63-1-152, a pharmacist may lawfully dispense naloxone to:

1. An individual at risk of experiencing an opioid overdose (first-party).
2. A family member, friend, or other person in a position to assist an individual at risk of experiencing an opioid overdose (third-party).
3. An organization, school, or municipal agency whose employees or volunteers encounter individuals at risk (entity dispensing).

The prescription may be processed and billed in the name of the family member or bystander seeking the medication.

---

5. Mandatory Overdose Recognition & Patient Education

Prior to dispensing naloxone under the statewide standing order, the pharmacist (or intern) must provide verbal and written instruction to the recipient covering the following mandatory clinical elements:

1. Overdose Recognition:
   • Profound central nervous system depression (unresponsiveness, stupor, coma).
   • Severe respiratory depression (slow, shallow breathing, agonal gasping, or apnea).
   • Physical signs: pinpoint pupils (miosis), cyanosis (blue/gray lips, fingernails), flaccid muscle tone, pale/clammy skin.
2. Emergency Response Steps:
   • Step 1: Assess & Stimulate: Check responsiveness using a vigorous sternal rub; shout the patient's name.
   • Step 2: Administer Naloxone: Administer 1 full spray of naloxone (4 mg) into one nostril (do not prime or test the spray). If using intramuscular injection, inject into the anterolateral thigh.
   • Step 3: Call 911 Immediately: Inform emergency dispatch that someone is unresponsive and not breathing normally.
   • Step 4: Support Breathing / CPR: Provide rescue breathing or chest compressions as trained.
   • Step 5: Recovery Position: If the patient breathes independently or vomits, position them on their side in the recovery position to prevent airway aspiration.
   • Step 6: Repeat Dose if Necessary: If the patient does not wake up or resume normal breathing within 2 to 3 minutes, administer a second dose of naloxone in the opposite nostril.
3. Post-Resuscitation Warnings:
   • Short Half-Life: Naloxone's therapeutic duration of action (30–90 minutes) is substantially shorter than many potent or extended-release opioids (methadone, oxycodone ER, fentanyl analogs). The patient may slip back into respiratory arrest as naloxone wears off.
   • Acute Withdrawal: Reversal will precipitate acute opioid withdrawal (agitation, tachycardia, diaphoresis, vomiting); the patient must be monitored until emergency medical responders arrive.

---

6. Statutory Immunity Protections (T.C.A. § 63-1-152(e))

To remove legal barriers and incentivize proactive overdose prevention, the Tennessee General Assembly enacted comprehensive statutory immunity provisions:

Tennessee Code Annotated § 63-1-152(e) Immunity Clause:

• Prescribers: Any licensed health care practitioner who issues the standing order or prescribes an opioid antagonist in good faith is immune from criminal prosecution and civil liability arising from the issuance or the subsequent administration of the drug.
• Pharmacists: Any licensed pharmacist who dispenses an opioid antagonist in good faith pursuant to a standing order or prescription is immune from criminal prosecution, civil damages, and professional disciplinary action by the Board of Pharmacy.
• Lay Responders / Bystanders: Any person who in good faith administers an opioid antagonist to another person whom they believe in good faith to be experiencing an opioid overdose is immune from civil damages and criminal prosecution resulting from such administration (codifying Good Samaritan protections).

This statutory shield protects healthcare professionals and community members from tort liability, medical malpractice claims, or criminal negligence charges, provided actions were performed in good faith and without gross negligence or wanton misconduct.